Stock KRRO KORRO BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
46.4 USD +3.71% Intraday chart for Korro Bio, Inc. -9.55% -3.19%
May. 15 HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating MT
May. 14 Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders.
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Frequency Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer
Frequency Therapeutics to Merge With Korro Bio in All-Stock Deal; Shares Rise Pre-Bell
Frequency Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Frequency Therapeutics, Inc. Announces Board Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRRO Stock
  4. News Korro Bio, Inc.
  5. Other languages